Matches in Wikidata for { <http://www.wikidata.org/entity/Q66067677> ?p ?o ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- Q66067677 description "clinical trial" @default.
- Q66067677 description "ensayu clínicu" @default.
- Q66067677 description "klinisch onderzoek" @default.
- Q66067677 description "клінічне випробування" @default.
- Q66067677 name "A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)" @default.
- Q66067677 name "A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)" @default.
- Q66067677 type Item @default.
- Q66067677 label "A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)" @default.
- Q66067677 label "A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)" @default.
- Q66067677 prefLabel "A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)" @default.
- Q66067677 prefLabel "A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)" @default.
- Q66067677 P1050 Q66067677-1AB7A220-83F2-4A6A-8F59-9E99B619DB16 @default.
- Q66067677 P1132 Q66067677-6A5E5057-5C94-4036-B0A4-14CCA9A5FFAD @default.
- Q66067677 P1476 Q66067677-12A3BD93-4525-48BA-B2E8-BA19FA0E3D22 @default.
- Q66067677 P2899 Q66067677-D1A6CFD8-BFAA-4D32-B7AE-11EDD1593884 @default.
- Q66067677 P3098 Q66067677-8DE66690-48AE-4DC4-B427-4735787781C2 @default.
- Q66067677 P31 Q66067677-AA3E73E5-674A-4F23-BC57-783569814AE9 @default.
- Q66067677 P4844 Q66067677-19A5CA19-533C-4F3A-846D-805120A310D5 @default.
- Q66067677 P580 Q66067677-610036AD-6E1C-4530-BCBD-75B8F45AD83E @default.
- Q66067677 P582 Q66067677-B5BBB3C7-5DED-4CCE-B1A1-06A5293D3E47 @default.
- Q66067677 P6099 Q66067677-62C1EF57-F493-45BC-B3B9-88F8DE37F67F @default.
- Q66067677 P6153 Q66067677-287D07DB-BB32-4639-A2A9-80F1FEC13639 @default.
- Q66067677 P6153 Q66067677-3232FDED-B415-459D-B51E-17B211A1BB71 @default.
- Q66067677 P8363 Q66067677-C0E0A313-B2C6-4D47-BED5-09E606738610 @default.
- Q66067677 P1050 Q208414 @default.
- Q66067677 P1132 "+100" @default.
- Q66067677 P1476 "A Phase I, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)" @default.
- Q66067677 P2899 "+18" @default.
- Q66067677 P3098 "NCT03930953" @default.
- Q66067677 P31 Q30612 @default.
- Q66067677 P4844 Q412323 @default.
- Q66067677 P580 "2019-05-01T00:00:00Z" @default.
- Q66067677 P582 "2024-05-13T00:00:00Z" @default.
- Q66067677 P6099 Q5452194 @default.
- Q66067677 P6153 Q266227 @default.
- Q66067677 P6153 Q777403 @default.
- Q66067677 P8363 Q78089383 @default.